Plasma Metabolic Outliers Identified in Estonian Human Knockouts
Authors:
- Ketian YuKYKetian Yu
- Estonian Biobank Research TeamETEstonian Biobank Research Team
- Tõnu EskoTETõnu Esko
- Mart KalsMKMart Kals
- Tiit NikopensiusTNTiit Nikopensius
- Jaanika KronbergJKJaanika Kronberg
- Urmo VõsaUVUrmo Võsa
- Arthur WusterAWArthur Wuster
- Lorenzo BombaLBLorenzo Bomba
Open Access
- 13 May 2025
- journal article
- research article
- Published by MDPI AG in Metabolites
- Vol. 15 (5) , 323
Abstract
Background/Objectives: Metabolomics, in combination with genetic data, is a powerful approach to study the biochemical consequences of genetic variation. We assessed the impact of human gene knockouts (KOs) on the metabolite levels of Estonia Biobank (EstBB) participants and integrated the results with electronic health record data. Methods: In 150,000 EstBB genotyped participants, we identified 723 KOs with 152 different predicted loss of function (pLoF) variants in 115 genes. For those KOs and 258 controls, 1387 metabolites were profiled using ultra-high-performance liquid chromatography–tandem mass spectrometry. Results: We identified 48 associations linking rare pLoF variants in 22 genes to 43 metabolites. Out of 48 associations, 27 (56%) were found in genes that cause inborn errors of metabolism. The top associations identified in our analysis included genes and metabolites involved in the degradation pathway of the pyrimidine bases uracil and thymine (DPYD and UPB1). We found DPYD gene KOs to be associated with elevated levels of Uracil, confirming that DPD-deficiency is a leading cause of severe 5-Fluorouracil toxicity. Overall, 54% of reported associations are gene targets of approved drugs or bioactive drug-like compounds. Conclusions: Our findings contribute to assessing the impact of human KOs on metabolite levels and offer insights into gene functions, disease mechanism, and drug target validation.Keywords
Funding Information
- Estonian Research Council (PRG1291)
- HPC servers of the University of Tartu (PRG1291)
- BioMarin Pharmaceutical Inc. (PRG1291)
This publication has 31 references indexed in Scilit:
- Identification of PCSK9-like human gene knockouts using metabolomics, proteomics, and whole-genome sequencing in a consanguineous populationCell Genomics, 2022
- Whole-exome sequencing identifies rare genetic variants associated with human plasma metabolitesThe American Journal of Human Genetics, 2022
- Improved imputation accuracy of rare and low-frequency variants using population-specific high-coverage WGS-based imputation reference panelEuropean Journal of Human Genetics, 2017
- Human Knockout Carriers: Dead, Diseased, Healthy, or Improved?Trends in Molecular Medicine, 2016
- Genotype Imputation with Millions of Reference SamplesThe American Journal of Human Genetics, 2016
- Analysis of p53 Transactivation Domain Mutants Reveals Acad11 as a Metabolic Target Important for p53 Pro-Survival FunctionCell Reports, 2015
- In vivo evidence that Agxt2 can regulate plasma levels of dimethylarginines in miceBiochemical and Biophysical Research Communications, 2013
- Human metabolic individuality in biomedical and pharmaceutical researchNature, 2011
- Genotype and phenotype in patients with dihydropyrimidine dehydrogenase deficiencyHuman Genetics, 1999
- β-Aminoisobutyric Acid (α-Methyl-β-Alanine): A New Amino-Acid Obtained from Human UrineNature, 1951